Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OsteGro
- Development stage
- Unknown
- Lead developer
- Elutia
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
OsteGro is an allograft bone matrix product line developed by Aziyo Biologics (now Elutia) designed to support bone repair and fusion in orthopedic, spinal, and dental procedures. The product family includes OsteGro V, a viable bone matrix that preserves native osteoprogenitor cells, and OsteGro Allograft Bone Matrix, a sterile scaffold composed of cancellous particles and demineralized cortical fibers. These products utilize a proprietary processing method to maintain the natural bone's osteoconductive scaffold, osteoinductive growth factors (such as bone morphogenetic proteins), and osteogenic potential. It is commonly employed in spinal fusions, hip reconstructions, and the treatment of complex fractures to promote robust new bone growth.
- Brand names
- OsteGroOsteGro V
- Other names
- Osteo Viable Matrix
Beyond the preview
Go deeper on OsteGro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OsteGro.